Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice.
1. What were the hottest topics and exciting new research from the ESMO Congress 2021? (00:18-05:00)
2. How will this key data impact the future of clinical practice? (05:00-06:28)
Disclosures: Axel S Merseburger has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In Prostate Cancer
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]
Axel Merseburger: Highlights of EAU23
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!